Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.CJ-66-0241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFPCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.
Stroke
September 2025
Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University.
Background: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain.
Methods: CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Non-disabling Cerebrovascular Events-II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles.
TMVR for the Treatment of Mitral Regurgitation: A State-of-the-Art Review.
Circ Cardiovasc Interv
September 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy (F.T., G.A., M.G., K.S., D.D., G.S., M.C.).
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the not negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly.
View Article and Find Full Text PDFAcute Lesion Visualization Following Interventional CMR Flutter Ablation Using PATRIOT CMR Imaging.
Circ Cardiovasc Imaging
September 2025
Department of Cardiology, Amsterdam UMC, The Netherlands. (L.H.G.A.H., N.v.P., M.J.B.K., P.B., C.A., M.J.W.G.).
Progress in the Study of Diagnostic Methods for Central Acute Vestibular Syndrome of a Vascular Cause.
Int J Gen Med
September 2025
Department of Neurology, Aerospace Center Hospital, Beijing, 100049, People's Republic of China.
Acute vestibular syndrome (AVS) is characterized by the sudden onset of dizziness or vertigo, accompanied by nausea, vomiting, gait instability, and nystagmus, lasting for more than 24 hours and often persisting for several days to weeks. Central AVS primarily involves central vestibular structures, such as the brainstem and cerebellum, and is most commonly caused by ischemic stroke in the posterior circulation. When acute posterior circulation infarction presents solely with isolated dizziness or vertigo, without other symptoms of central nervous system damage, it is often misdiagnosed as a peripheral vestibular disorder, this can lead to serious consequences.
View Article and Find Full Text PDF